Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of AP31969 versus placebo for rhythm control in atrial fibrillation
2025-521377-14-00Phase 2Authorised
- Sponsor
- Acesion Pharma
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing AP31969 with Placebo (2 arms). Primary endpoint: Atrial fibrillation burden. Planned start Oct 2025; status: authorised.
02
Drugs
AP31969
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2025-521377-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521377-14-00.